Also trades as: 0460.HK (HKSE) · $vol 3M
SHPHF OTC
Sihuan Pharmaceutical Holdings Group Ltd.
1W: +0.0%
1M: +0.0%
3M: -7.5%
YTD: -25.0%
1Y: +21.7%
3Y: +58.7%
5Y: -41.4%
$0.12
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$1.9B
+2.2% ▲
5Y CAGR: -8.0%
Gross Profit
$1.2B
-4.2% ▼
5Y CAGR: -11.5%
Operating Income
-$138M
-185.4% ▼
Net Income
-$217M
-301.1% ▼
EPS (Diluted)
$-0.02
-303.4% ▼
EBITDA
$105M
-68.6% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $2.5B | $3.0B | $2.2B | $1.9B | $1.9B |
| YoY Growth | -14.4% | +23.3% | -28.2% | -14.7% | +2.2% |
| Cost of Revenue | $550M | $608M | $694M | $565M | $659M |
| Gross Profit | $1.9B | $2.4B | $1.5B | $1.3B | $1.2B |
| Gross Margin | 77.7% | 80.0% | 68.2% | 69.6% | 65.3% |
| R&D Expenses | $729M | $868M | $1.1B | $592M | $474M |
| SG&A Expenses | $859M | $1.1B | $1.0B | $911M | $1.2B |
| Operating Expenses | $1.1B | $1.7B | $3.3B | $1.1B | $1.4B |
| Operating Income | $787M | $772M | -$1.8B | $162M | -$138M |
| Operating Margin | 31.9% | 25.4% | -83.9% | 8.7% | -7.3% |
| Interest Expense | $8M | $117M | $211M | $269M | $275M |
| Income Before Tax | $766M | $496M | -$2.1B | -$161M | -$428M |
| Tax Expense | $219M | $253M | $197M | $96M | $43M |
| Net Income | $473M | $417M | -$1.9B | -$54M | -$217M |
| Net Margin | 19.2% | 13.7% | -87.8% | -2.9% | -11.4% |
| EPS (Diluted) | $0.05 | $0.04 | $-0.21 | $-0.01 | $-0.02 |
| EBITDA | $714M | $932M | -$1.5B | $334M | $105M |
| Shares Outstanding | 9.47B | 9.48B | 9.33B | 9.30B | 9.27B |